Expression of claudin-1, claudin-4 and zonula occludens-1 in cervical intraepithelial neoplasia and invasive squamous cell carcinoma.
- Author:
Seon Kyoung LEE
1
;
Hyun Kyung RHO
;
Tai Yang PARK
;
Kue Hyun KANG
;
Tae Il CHO
;
Tae Jin LEE
Author Information
1. Department of Obstetrics and Gynecology, Sungae Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Claudin-1;
Claudin-4;
ZO-1;
CIN;
Cervical Cancer
- MeSH:
Carcinoma, Squamous Cell*;
Cervical Intraepithelial Neoplasia*;
Cervix Uteri;
Claudin-1*;
Claudin-4*;
Claudins;
Extracellular Matrix;
Female;
Tight Junction Proteins;
Uterine Cervical Neoplasms
- From:Korean Journal of Obstetrics and Gynecology
2007;50(10):1378-1385
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Cell to cell and cell to extracellular matrix interaction are crucial in tumor development and progression. Tight junction proteins such as claudins and zonula occludens-1 (ZO-1) play an important role in these processes. This study was performed to investigate the difference of expressions of claudin-1, claudin-4 and ZO-1 in low grade squamous intraepithelial lesion (LSIL), high grade squamous intraepithelial lesion (HSIL), and invasive squamous cell carcinoma (ISCC) of the uterine cervix. METHODS: The expressions of claudin-1, claudin-4 and ZO-1 were evaluated using immunohistochemical staining in 78 cervical tissue specimens (LSIL 22 case, HSIL 36 case, and ISCC 20 case). RESULTS: Claudin-1 expression was positive in 40.9% of LSIL, in 94.0% of HSIL and in 20.0% of ISCC. The expression of claudin-1 was significantly high in HSIL (p=0.0001). Claudin-4 expression was positive in 31.8% of LSIL, in 41.7% of HSIL and in 25.0% of ISCC. The expression of claudin-4 was high in HSIL, but it was not statistically different. ZO-1 expression was positive in 13.6% of LSIL, in 41.7% of HSIL, and in 25.5% of ISCC. The expression of ZO-1 was significantly high in HSIL (p=0.011). CONCLUSION: These results indicate increased expressions of claudin-1 and ZO-1 in the HSIL that includes cervical intraepithelial neoplasia (CIN) 2 and 3, which decrease during progression to cervical cancer.
